Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modigraf in Pediatric Liver and Kidney Transplant
NCT05153915Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2021
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus + Wuzhi capsule in Liver transplant rejection and kidney transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoints: Percentage of Participants With Acute Rejection (AR) at 12 months, Percentage of Participants with Biopsy-Proven Acute Rejections (BPAR) at 12 months and 4 more. Started Dec 2021; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
Liver transplant rejectionkidney transplant rejection
Beyond the preview
Go deeper on NCT05153915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153915.